ArticleIndian dermatology online journal2026
Serum CXCL10 Levels in Non-Segmental Vitiligo and Its Correlation with Dermoscopic Findings and Disease Severity: A Cross-Sectional Study.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Perspectives in Vitiligo: Pathogenesis, Treatment, and Biomarker Development.Indian dermatology online journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCXCL10 (C-X-C motif chemokine ligand 10) is a chemokine induced by interferon-γ that is crucial in the recruitment of CD8+ (cluster differentiation) T cells to the sites of depigmentation in vitiligo. It has emerged as a potential biomarker for disease activity. However, its correlation with dermoscopic patterns and clinical severity in non-segmental vitiligo remains underexplored. AIM AND
objectivesTo estimate serum CXCL10 levels in patients with non-segmental vitiligo in comparison to healthy controls and to correlate CXCL10 levels with dermoscopic findings and clinical severity. PATIENTS AND
methodsThis cross-sectional study comprised 80 patients and 40 age- and sex-matched healthy controls. Participants underwent clinical evaluation, dermoscopy (BPLeFoSK scoring), and assessment of disease activity and severity using Vitiligo Disease Activity Score (VIDA) and Vitiligo Area Scoring Index (VASI) scores, respectively. Serum CXCL10 levels were measured using enzyme-linked immunosorbent assay (ELISA).
resultsThe mean serum CXCL10 level was markedly increased in vitiligo patients (118.7 ± 78.0 pg/mL) compared to controls (35.6 ± 37.9 pg/mL, P < 0.001). Levels were notably higher in active (154.0 ± 77.8 pg/mL) than stable disease (61.3 ± 23.9 pg/mL, P < 0.001). A strong inverse correlation was found between CXCL10 and the BPLeFoSK score ( r = -0.613, P < 0.001), and a positive correlation with the VIDA score ( P < 0.001). Dermoscopic features, such as poorly defined borders, absent perifollicular pigmentation, and micro-Koebnerization, were significantly associated with higher CXCL10 levels ( P < 0.05). LIMITATIONS: This cross-sectional study design precludes the evaluation of causality or treatment response. CXCL10 levels were measured at a single time point, limiting insights into temporal variation.
conclusionSerum CXCL10 is significantly elevated in active non-segmental vitiligo and correlates well with disease activity and VIDA score. It shows promise as a noninvasive biomarker for monitoring disease activity but not for assessing disease extent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.